How Much Is Wegovy? The Price Per Month, Channel by Channel

What Wegovy Costs Without Insurance

Start with the number nobody wants to pay. Wegovy (semaglutide 2.4mg injection) is made by Novo Nordisk, and its sticker price is the benchmark every cheaper channel is measured against. It is worth knowing this figure precisely, because the entire point of shopping by channel is to never actually hand it over.

The wholesale acquisition cost (WAC) for Wegovy is roughly $1,349 per month, and it is identical at every dose. That WAC is what pharmacies pay before rebates, and it is almost exactly what you will be quoted at the counter if you walk in with no card, no coupon, and no coverage — the true Wegovy cost without insurance. Hold this number in mind: every option below is a discount off it.

• Wegovy 0.25mg (starting dose): $1,349/month
• Wegovy 0.5mg: $1,349/month
• Wegovy 1.0mg: $1,349/month
• Wegovy 1.7mg: $1,349/month
• Wegovy 2.4mg (maintenance dose): $1,349/month

The flat-rate structure has a real budgeting consequence: you pay full freight for the first four months of titration, when you are on tiny starter doses, exactly the same as you do at the full 2.4mg maintenance dose. There is no "ramp-up discount," so any channel that lowers your monthly Wegovy price applies from your very first pen — another reason to lock in a cheaper route before you ever start.

The NovoCare Self-Pay Card: $199/Month

For most cash payers, the NovoCare self-pay card is the channel that does the heavy lifting. Novo Nordisk stood it up in early 2026 to stop bleeding customers to Eli Lilly's LillyDirect, and it drops the injectable Wegovy price per month to a flat $199 for people paying out of pocket. That single card turns a four-figure prescription into something closer to a gym membership.

The terms that actually matter when you price it out:

• Price: $199/month for all Wegovy injection doses
• Duration: Introductory offer valid through June 2026
• Eligibility: Patients without insurance coverage for Wegovy, or those whose insurance denies the claim
• How to access: Through NovoCare.com or participating telehealth providers
• Limitation: Cannot be combined with government insurance (Medicare, Medicaid, Tricare)

At $199, the NovoCare card lands about 85% below the counter price — and it noticeably undercuts Eli Lilly's rival channel, where Zepbound has sold for $349/month through LillyDirect since late 2024. In other words, the cheapest injectable GLP-1 you can buy with a manufacturer card is now Wegovy, not the competition.

Oral Wegovy: The Cheapest Brand Route at $149

If your only goal is the lowest possible Wegovy price per month from the manufacturer itself, the oral tablet is the answer. Oral Wegovy (semaglutide 50mg, taken daily) reached pharmacies in January 2026 and quietly became the cheapest brand-name channel of all — and you swallow it instead of injecting it.

What it actually costs:

• Lowest dose (starting): $149/month self-pay
• Maintenance dose: Pricing varies; typically $149–$299/month depending on dose and pharmacy
• With commercial insurance: Copays as low as $25/month with the NovoCare Savings Card

The catch is a routine, not a cost: the tablet has to be taken on an empty stomach with no more than 4 ounces of water, at least 30 minutes before any food, drink, or other medication. Stick to that and the payoff matches the pen — trials showed roughly 15–17% body weight loss over 68 weeks for the oral version, on par with injectable Wegovy.

The headline for budget-driven shoppers: at $149, oral Wegovy is the cheapest FDA-approved semaglutide channel on the market. It even prices below most compounded vials — so for the first time, the lowest-cost route and the fully-approved route are the same route.

Your Wegovy Copay With Insurance

If your plan covers Wegovy, insurance is usually the cheapest channel of all — but "if" is carrying a lot of weight. Coverage has widened a lot since the 2021 launch, yet what you actually pay still depends almost entirely on your specific plan. Here is the range to price against:

• Typical copay with commercial insurance: $25–$200/month
• With Novo Nordisk Savings Card + insurance: As low as $0 for 3 months, then $25–$50/month
• Prior authorization required: Nearly always — expect your doctor to document BMI of 30+ (or 27+ with a weight-related condition)
• Step therapy: Some insurers require trying cheaper alternatives first (e.g., phentermine, orlistat)

Whether this channel is even open to you comes down to who pays your premiums. Large employers in tech, finance, and healthcare increasingly fold GLP-1s into their formularies; small employers and high-deductible plans frequently carve them out entirely. Check your formulary before you assume insurance is your cheapest route — if Wegovy is excluded, the $199 NovoCare card or the $149 tablet will beat a high deductible every time.

If you get denied:don't just default to self-pay. Ask your doctor to file a peer-to-peer review plus an appeal letter citing the 2022 AAP clinical practice guidelines. Roughly 40–60% of appeals succeed for patients who clearly meet the BMI criteria — and a winning appeal can be cheaper than any cash channel on this page.

The Medicare Price Starting July 2026

For anyone on Medicare, a brand-new channel is about to open that may beat every cash option. Starting July 2026, Medicare Part D will cover Wegovy and Zepbound for obesity through a CMS-negotiated Bridge program, pricing the medication at a level no self-pay card can match. Here is how that channel will work:

• Estimated copay: $50/month for eligible beneficiaries
• Eligibility: BMI of 30 or above, or BMI 27+ with at least one weight-related condition
• Prior authorization: Required; must be submitted by treating physician
• Covered medications: Wegovy (injectable and oral), Zepbound
• Not covered: Ozempic prescribed off-label for weight loss

The price drop here is enormous in context: Medicare had banned weight-loss drug coverage outright since 2003, so beneficiaries previously faced the full $1,349 or nothing. Roughly 3.4 million people who meet the clinical criteria are expected to gain access to a roughly $50/month channel overnight — making Medicare the single cheapest Wegovy route for those who qualify.

For a complete breakdown, see our Medicare GLP-1 Coverage Guide.

Cheaper Semaglutide Routes Compared

Until recently, the cheapest semaglutide of any kind came from compounding pharmacies and telehealth platforms, priced anywhere from $149–$499/month. That channel used to win on price alone — but the math has changed, and so has the legality:

• The FDA declared the semaglutide shortage officially over in late 2024
• Without an active shortage, 503A compounding pharmacies lose their legal basis to compound copies of brand-name drugs
• The FDA has issued warning letters to more than 50 compounders
• Several major telehealth platforms have stopped offering compounded semaglutide

It is also worth what you save: compounded semaglutide is not FDA-approved and skips the potency testing, sterility standards, and manufacturing controls that brand Wegovy goes through. The FDA has logged cases of sub-potent and contaminated batches, which is a real cost even when the price tag looks lower.

The bottom line on price: now that oral Wegovy sits at $149/month, the cheaper-compounded argument has basically collapsed — you can get the approved version for the same money. Our compounded vs brand comparison runs the full cost breakdown side by side.

NovoCare Cards & Manufacturer Savings

NovoCare is really an umbrella over several distinct price channels — which one applies to you depends on your coverage and income. Here is how each lowers the Wegovy price per month: